OncoSeq:BRCAXL
Hereditary Cancer panel (germline) clinical report- ATM, APC, BARD 1, BRCA 1, BRCA 2, BRIP 1, CDH 1, CHEK 2, EPCAM, MLH 1, MSH 2, MSH 6, MUTYH, NBN, PALB 2, PMS 2, PTEN, RAD 50, RAD 51 C, RAD 51 D, STK 11 and TP53 ( SNPs & indel)
Output Report: fastq file
TEST CODE: 24101
OncoSeq:BRCAXL+
Hereditary Cancer panel (germline) clinical report- ATM, APC, BARD 1, BRCA 1, BRCA 2, BRIP 1, CDH 1, CHEK 2, EPCAM, MLH 1, MSH 2, MSH 6, MUTYH, NBN, PALB 2, PMS 2, PTEN, RAD 50, RAD 51 C, RAD 51 D, STK 11 and TP53 ( SNPs & indel) with clinical report
Output Report: Clinical report
TEST CODE: 24102
 Turnaround time | 3 weeks for OncoSeq 22 4 weeks for OncoSeq 22 + |
 Preferred specimen type | DNA |
| Alternate specimen type | Peripheral Blood |
TEST INFORMATION
How Hereditary Cancer screening works?
Agiomix Hereditary Cancer Panel uses Next Generation Sequencing to analyse mutations in the following genes: ATM, APC, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, PTEN, RAD50, RAD51C, RAD51D, STK11 and TP53.
Agiomix uses clinically validated kits for Germline analysis (SNPs & INDELs) of DNA extracted from blood.
The Hereditary Cancer Panel uses specific bidirectional amplicon libraries for Next Generation Sequencing on the illumina MiSeq System:
- Panel size: 145 kb
- Coverage: Full exons plus 20bp padding regions
What is the information provided in the Report?
Agiomix provides a comprehensive clinical report reviewed by our Medical Board of Consultants and Genetic Experts. Pre and post-test consultation are also available to insure the complete understanding of the results.
